Login / Signup

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.

Wolfram DöhnerStefan D AnkerJaved ButlerFaiez ZannadGerasimos FilippatosJoão Pedro FerreiraAfshin SalsaliCarolyn KaempferMartina BrueckmannStuart J PocockJames L JanuzziMilton Packer
Published in: European heart journal (2022)
Hyperuricaemia is common in HF and is an independent predictor of advanced disease severity and increased mortality. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to hyperuricaemia. The benefit of empagliflozin on the primary outcome was observed independently of SUA.
Keyphrases